Oculis Holding AG
IPOGlobal Biopharmaceutical Company Driven To Save Sight & Improve Eye Care
Public · Reykjavik, Switzerland · Founded 2017 · $92.9M raised
- Headquarters
- Reykjavik
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B
- Website
- oculis.com
- Total Funding
- $92.9M
- Last Round
- $57.0M Series CMay 2021
- Rounds
- 3
- Type
- Public
About
Clinical-stage biopharmaceutical company developing innovative therapies for ophthalmic diseases to save and restore sight.
Summary
Oculis Holding AG is a Biotech company based in Reykjavik, Switzerland, founded in 2017. It has raised $92.9M in total across 3 rounds, most recently a $57.0M Series C round in May 2021. Investors include Brunnur Ventures, Earlybird Venture Capital and Bay City Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
May 2021
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...